Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lucid Diagnostics (LUCD) Non-cash Items (2021 - 2026)

Lucid Diagnostics posted quarterly Non-cash Items of $472000.0 for Q1 2026, down 76.28% year-on-year from $2.0 million in Q1 2025, and up 19.19% on a QoQ basis from $396000.0 in Q4 2025.

Lucid Diagnostics (LUCD) has 6 years of Non-cash Items data on file, last reported at $472000.0 in Q1 2026.

  • For the quarter ending Q1 2026, Non-cash Items fell 76.28% year-over-year to $472000.0; the trailing twelve-month figure through Mar 2026 stood at $472000.0 (down 76.28% YoY), and the FY2025 full-year result was $396000.0, up 98.99% from the prior year.
  • Non-cash Items for Q1 2026 stood at $472000.0, up from $396000.0 in the prior quarter.
  • Across five years, Non-cash Items topped out at $2.0 million in Q1 2025 and bottomed at $499.0 in Q3 2022.
  • The 5-year median for Non-cash Items is $347000.0 (2023), against an average of $438878.3.
  • The widest annual swing landed in 2023, when Non-cash Items jumped 69439.08%; it then tumbled 76.28% in 2026.
  • A 5-year view of Non-cash Items shows it stood at $428000.0 in 2022, then soared by 78.74% to $765000.0 in 2023, then sank by 73.99% to $199000.0 in 2024, then surged by 98.99% to $396000.0 in 2025, then gained by 19.19% to $472000.0 in 2026.
  • The last three Non-cash Items figures came in at $472000.0 (Q1 2026), $396000.0 (Q4 2025), and $307000.0 (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn
10 Lucid Diagnostics 145.00 Mn 117.12 Mn -325,000.00

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 472,000.00
Mar 31, 2026 472,000.00
Dec 31, 2025 396,000.00
Dec 31, 2025 396,000.00
Sep 30, 2025 307,000.00
Sep 30, 2025 307,000.00
Jun 30, 2025 446,000.00
Jun 30, 2025 446,000.00
Mar 31, 2025 1.99 Mn
Mar 31, 2025 1.99 Mn
Dec 31, 2024 199,000.00
Dec 31, 2024 199,000.00
Sep 30, 2024 197,000.00
Sep 30, 2024 197,000.00
Jun 30, 2024 199,000.00
Jun 30, 2024 199,000.00
Mar 31, 2024 195,000.00
Mar 31, 2024 195,000.00
Dec 31, 2023 765,000.00
Dec 31, 2023 765,000.00
Sep 30, 2023 347,000.00
Sep 30, 2023 347,000.00
Jun 30, 2023 641,000.00
Jun 30, 2023 641,000.00
Mar 31, 2023 676.00
Mar 31, 2023 676.00
Dec 31, 2022 428,000.00
Dec 31, 2022 428,000.00
Sep 30, 2022 499.00
Sep 30, 2022 499.00
Dec 31, 2021 6,665.00
Dec 31, 2021 6,665.00